Model-based optimization of rituximab dosing regimen in follicular non-hodgkin lymphoma
|
|
- Vernon Bond
- 6 years ago
- Views:
Transcription
1 Model-based optimization of rituximab dosing regimen in follicular non-hodgkin lymphoma D. Ternant, E. Hénin, G. Cartron, M. Tod, G. Paintaud, P. Girard
2 Introduction Objectives Introduction Rituximab in follicular lymphoma Rituximab : Monoclonal antibody targeted against human CD20 Large variability of concentration-effect relationship due to: Pharmacokinetic variability : efficacy for concentrations FCGR3A polymorphism: Progression-free survival () FCGR3A-VV > F carriers (Igarashi et al. 2002) Proportions VV (15%) Fx (85%) (Lejeune et al. 2009) Cartron,
3 Introduction Objectives Introduction Initial dosing regimen : induction treatment by 4 weekly 375 mg/m 2 injections number of injections, maintenance treatment: Progression-free survival R-CHOP + R maintenance R-CHOP + Observation van Oers,
4 Introduction Objectives Introduction The dosing regimen may be optimized: Increasing infusion dose Adjusting dosing regimen according to FCGR3A genotype But not confirmed by specific studies Clinical trial simulation But No PK-PD study of rituximab in FL 4
5 Introduction Objectives Model Building Objectives Build and evaluate a dose efficacy model of rituximab in follicular lymphoma Using data from literature Considering FCGR3A genotype Simulate dose efficacy relationship for several dosing regimens 5
6 Objectives Model building Model building Data Berinstein, 1998 McLaughlin, 1998 Weng, 2004 Pivotal study graphical extraction Model Median rituximab concentrations VV, Fx Estimation 2 compartment model Median PK parameters Estimation PD parameters Estimation PD parameters for FCGR3A Time-to-event model 6
7 Objectives Model building Model building Data Berinstein, 1998 McLaughlin, 1998 Weng, 2004 Pivotal study graphical extraction Model Median rituximab concentrations VV, Fx Estimation 2 compartment model Median PK parameters Estimation PD parameters Estimation PD parameters for FCGR3A Time-to-event model 7
8 Objectives Model building Pharmacokinetic model Median concentrations of Berinstein et al. 2-compartment model Median PK parameters Winnonlin Professional 4.1 RTX concentration Berinstein, 1998 Vc = 2.4 L CLc = L/h Vp = 3.7 L CLp = L/h Obs (T) Pred (T) Time (hours) 8
9 Objectives Model building Time-to-event model Data Berinstein, 1998 McLaughlin, 1998 Weng, 2004 Pivotal study graphical extraction Model Median rituximab concentrations VV, Fx 2 compartment model Median PK parameters Estimation PD parameters Estimation PD parameters for FCGR3A Time-to-event simulation model 9
10 Objectives Model building Time-to-event model ( t) = exp( ' * t) ( ) & Cm * = * ( $ max 1 ' ) ) % Cm50 + Cm Cm t n ' t = AUC t n t n ' t ' t = + t t n C t n #! " (, ) ' t d, λ : hazard function λ max : maximum hazard (no rituximab efficacy) Cm : mean-time concentration Cm 50 : Cm leading to 50% of λ max γ : shape factor 10
11 Objectives Model building Time-to-event model Time-to-event model: parameter estimation Cm 50, γ: estimated Median pharmacokinetics (Cm, Berinstein, 1998 ) (McLaughlin, 1998 ) McLaughlin, 1998 Progression-free survival λ max = 0.16 month -1 Cm 50 = 35.1 mg/l γ = Time (months) 11
12 Objectives Model building Influence of FCGR3A Data Berinstein, 1998 McLaughlin, 1998 Weng, 2004 graphical extraction Model Median rituximab concentrations VV, Fx Estimation Median concentrations 2 compartment model Estimation λ max, Cm 50, γ Estimation Cm 50,VV,Cm 50,Fx γ VV, γ Fx Time-to-event simulation model 12
13 Objectives Model building Influence of FCGR3A γ values for VV and Fx were fixed: γ Fx = γ = 0.5. γ VV = 2 Estimation of Cm 50,VV and Cm 50,Fx VV and Fx (24 months) Weng, Cm 50,VV = 7.9 mg/l Cm 50,Fx = 78.9 mg/l HR Fx/VV = 2.5 McLaughlin, 1998: # # Fx, M 24 VV, M 24 = # ˆ = # ˆ M 24 M 24 " HR HR 1! 0.85 Fx/ VV 1! 0.15 Fx/ VV # # Fx, M 24 VV, M 24 = # ˆ = # ˆ M 24 M 24 " HR HR 1! 0.85 Fx / VV VV (15%) HR Fx/VV = 2.5 1! 0.15 Fx / VV Overall Fx (85%) Then calculation of Cm 50,VV and Cm 50,Fx by solving the equations: 24 months TTP genotype (24M) = f (Cm 50,genotype ) 13
14 Objectives Model building Simulation model Data Berinstein, 1998 McLaughlin, 1998 Weng, 2004 graphical extraction Model Median rituximab concentrations VV, Fx Estimation Median concentrations 2 compartment model Estimation λ max, Cm 50, γ Estimation Cm 50,VV,Cm 50,Fx γ VV, γ Fx Ng, 2005 Population PK parameters Time-to-event simulation model ω Cm50 = 50% 14
15 Objectives Model building Simulation model Simulation of published studies Number of patients = eligible patients of the study Number of simulations = 500 Evaluation: visual predictive checks (VPC) observed model-predicted (90% confidence interval) Trial simulator II.2, S-Plus
16 Model Building Dose alteration Evaluation van Oers, 2006 Cartron, 2002 graphical extraction CHOP R-CHOP + obs R-CHOP + maint Individual TTP VV, Fx TTE simulation model TTE simulation model Internal evaluation (Pivotal) (Weng) Analysis of sensitivity (Pivotal) (Weng) External evaluation (van Oers) (Cartron) 16
17 Model Building Dose alteration Internal evaluation van Oers, 2006 Cartron, 2002 graphical extraction CHOP R-CHOP + obs R-CHOP + maint Individual TTP VV, Fx TTE simulation model TTE simulation model Internal evaluation (Pivotal) (Weng) Analysis of sensitivity (Pivotal) (Weng) External evaluation (van Oers) (Cartron) 17
18 Model Building Dose alteration Internal evaluation Pivotal study (McLaughlin et al. 1998) * 375 mg/m 2 /week confidence interval 90% 500 simulations C 95 C 50 C observed Time (months) 18
19 Model Building Dose alteration Internal evaluation Influence of FCGR3A genotype : Weng et al M24 4 * 375 mg/m 2 /week 0.6 VV Progression free survival Fx Time (months) 19
20 Model Building Dose alteration External evaluation van Oers, 2006 Cartron, 2002 graphical extraction CHOP R-CHOP + obs R-CHOP + maint Individual TTP VV, Fx TTE simulation model TTE simulation model Internal evaluation (Pivotal) (Weng) Analysis of sensitivity (Pivotal) (Weng) External evaluation (van Oers) (Cartron) 20
21 Model Building Dose alteration External evaluation Studies Van Oers et al.2006 : of relapsed/resistent FL patients treated with: R-CHOP R-CHOP + rituximab maintenance (375 mg/m 2 every 3 months) Cartron et al., 2002 : of first-line FL VV et Fx patients (rituximab 4 x 375 mg/m 2 ) 21
22 Model Building Dose alteration External evaluation Van Oers et al. R-CHOP Without maintenance R-CHOP With maintenance 6 * 375 mg/m 2 /21d 6 * 375 mg/m 2 /21d mg/m 2 /3months 1.0 M M progression free survival progression free survival Time (months) Time (months) 22
23 Model Building Dose alteration Cartron et al., x 375 mg/m 2 /week. 1.0 M VV Progression free survival Fx Time(months) 23
24 Model Building Dose alteration Conclusion: model Satisfactory description of rituximab within M24 With and without rituximab maintenance For both FCGR3A genotypes (M24) : metrics 24
25 Model Evaluation Dose alteration Conclusion Dosing regimen alteration Rituximab monotherapy (Cartron et al. 2002) : Fx vs. VV 4 weekly doses + maintenance every 2 months Dose alteration Induction : 375, 750, 1500, 2250 mg/m 2 Maintenance : 375, 750, 1500, 2250 mg/m 2 25
26 Dose alteration Conclusion Conclusion and perspectives Main benefit : increase of maintenance dose of Fx never reach of VV Perspectives Improvement of the model : Tumor burden, stage of disease alteration of induction dose and schedule Confirmation by clinical trials 26
27 References Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and antitumor response in the treatment of recurrent low-grade or follicular non-hodgkin's lymphoma. Ann Oncol. 1998; 9: Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-cd20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002; 99: Lejeune J, Thibault G, Ternant D, et al. Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol. 2008; 26: ; author reply Epub 2008 Oct 27. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma. J Clin Oncol McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-cd20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998; 16: Ng CM, Bruno R, Combs D, et al. Population pharmacokinetics of rituximab (anti-cd20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol. 2005; 45: van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006; 108:
28 Objectives Model building Time-to-event model Parameter estimation λ max : fixed Rituximab (R) combined with chemotherapy (X) λ max = λ X R alone Effects for R and X are assumed to be independent HR 0/R = HR X/R-X λ max = λ R x HR X/R-X HR X/R-X : Marcus et al.,
29 Model Building Dose alteration Internal evaluation Sensitivity analysis (fixed parameters) A 0.6 McLaughlin, 1998 Weng, B 0 10% 50% 150% Cm50 max VV VV 29
30 Mean-time concentration AUC(t) C(t) 30
31 Model parameters AUC(t) Cm(t) C(t) 31
TRANSPARENCY COMMITTEE OPINION. 8 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,
More informationWhat Is the Role of Maintenance Rituximab in Follicular NHL?
Review Article [1] January 01, 2008 By David G. Maloney, MD, PhD [2] Recent trials have demonstrated improvements in progression-free and overall survival with the inclusion of the chimeric anti-cd20 monoclonal
More informationRationale for optimal obinutuzumab/ga101 dosing regimen in B-cell non-hodgkin lymphoma
Published Ahead of Print on December 11, 2015, as doi:10.3324/haematol.2015.133421. Copyright 2015 Ferrata Storti Foundation. Rationale for optimal obinutuzumab/ga101 dosing regimen in B-cell non-hodgkin
More informationORIGINAL ARTICLE. Suresh Advani 1, Shubhadeep Sinha 2, Pankaj Thakur 3, Neetu Naidu 3, Sreenivas Chary 3, Ghanshyam Biswas 4, Vamsi Krishna Bandi 5
58 ORIGINAL ARTICLE Efficacy, Safety and Immunogenecitystudy of Intravenous Infusion of Rituximab (Hetero) and Reference Medicinal Product (Rituximab, Roche) in Indian Patients of Follicular Lymphoma Preliminary
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationNCCP Chemotherapy Protocol. Maintenance therapy for the treatment of follicular CD20 positive, B-cell NHL patients responding to induction therapy.
RiTUXimab 375mg/m 2 Therapy-Follicular Lymphoma INDICATIONS FOR USE: INDICATION Maintenance therapy for the treatment of follicular CD20 positive, B-cell NHL patients responding to induction therapy. Monotherapy
More informationThe case for maintenance rituximab in FL
New-York, October 23 rd 2015 The case for maintenance rituximab in FL Pr. Gilles SALLES For FL patients, progression-free survival still needs to be improved Median R-CHVP-I 66 months P
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 MABTHERA 100 mg, concentrate for solution for infusion B/2 (CIP code: 560 600-3) MABTHERA 500 mg, concentrate
More informationPharmacokinetics of rituximab and its clinical use: Thought for the best use?
Critical Reviews in Oncology/Hematology 62 (2007) 43 52 Pharmacokinetics of rituximab and its clinical use: Thought for the best use? Guillaume Cartron a,b,,hélène Blasco c, Gilles Paintaud a,c, Hervé
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationeastern cooperative oncology group Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning
Results of E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Indolent B-Cell Lymphoma Michael Williams, Fangxin Hong, Brad Kahl, Randy
More informationOutcomes of Treatment in Slovene Follicular Lymphoma Patients
Original Study Outcomes of Treatment in Slovene Follicular Lymphoma Patients Tanja Juznic Setina, Simona Borstnar, Barbara Jezersek Novakovic Abstract The treatment outcomes of follicular lymphoma (FL)
More informationRituxan Hycela. Rituxan Hycela (rituximab and hyaluronidase human) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.96 Subject: Rituxan Hycela Page: 1 of 5 Last Review Date: September 15, 2017 Rituxan Hycela Description
More informationScottish Medicines Consortium
Scottish Medicines Consortium rituximab 10mg/ml concentrate for infusion (MabThera ) Roche (No.330/06) 10 November 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationPatterns of Care in Medical Oncology. Follicular Lymphoma
Patterns of Care in Medical Oncology Follicular Lymphoma CASE 1: A 72-year-old man with multiple comorbidities including COPD/asthma presents with slowly progressive cervical adenopathy. Bone marrow biopsy
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More informationBrad S Kahl, MD. Tracks 1-21
I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationJonathan W Friedberg, MD, MMSc
I N T E R V I E W Jonathan W Friedberg, MD, MMSc Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division at the University of Rochester s James P Wilmot Cancer
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationRITUXAN (rituximab and hyaluronidase human)
Drug Prior Authorization Guideline RITUXIMAB products J9310 RITUXAN (rituximab and hyaluronidase human) PA9847 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria
More informationTraditional Therapies for Waldenstrom s Macroglobulinemia. Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014
Traditional Therapies for Waldenstrom s Macroglobulinemia Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014 Jeff Atlin (1953-2014) Standard treatment options Single drug therapies
More informationCorporate Medical Policy
Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia
More informationCPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults
MANAGEMENT IN CONFIDENCE CPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults The Benefits of the Proposition
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationCost-effectiveness of Obinutuzumab (Gazyvaro ) for the First Line Treatment of Follicular Lymphoma
Cost-effectiveness of Obinutuzumab (Gazyvaro ) for the First Line Treatment of Follicular Lymphoma The NCPE has issued a recommendation regarding the cost-effectiveness of obinutuzumab (Gazyvaro ). Following
More informationMathias J Rummel, MD, PhD
I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track
More informationRituximab for the first-line treatment of stage III-IV follicular lymphoma
Rituximab for the first-line treatment of stage III-IV (review of guidance 110) Issued: January 2012 guidance.nice.org.uk/ta243 NICE has accredited the process used by the Centre for Health Technology
More informationNCCN Non Hodgkin s Lymphomas Guidelines V Update Meeting 06/14/12 and 06/15/12
NCCN Non Hodgkin s Lymphomas Guidelines V.1.213 Update Meeting 6/14/12 and 6/15/12 Guidelines Page and Request Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Panel Discussion References
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationRituximab in Lymphoma and Chronic Lymphocytic Leukemia: A Clinical Practice Guideline, Version 3
A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Rituximab in Lymphoma and Chronic Lymphocytic Leukemia: A Clinical Practice Guideline, Version 3 A. Prica, F.
More informationNon Transplant-Related Treatment Options in Follicular Lymphoma
Biology of Blood and Marrow Transplantation 12:53-58 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0111$32.00/0 doi:10.1016/j.bbmt.2005.10.003 Non Transplant-Related
More informationREPEATED B CELL DEPLETION IN TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
ARD Online First, published on November 3, 2005 as 10.1136/ard.2005.044487 REPEATED B CELL DEPLETION IN TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS Concise report Kristine P. Ng 1 Maria J. Leandro
More informationPredictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma
ONCOLOGY REPORTS 24: 1101-1107, 2010 Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma MATEJA HORVAT 1, VERONIKA KLOBOVES PREVODNIK 2, JAKA LAVRENCAK 2 and
More informationpan-canadian Oncology Drug Review Initial Economic Guidance Report Obinutuzumab (Gazyva) for Follicular Lymphoma August 30, 2018
pan-canadian Oncology Drug Review Initial Economic Guidance Report Obinutuzumab (Gazyva) for Follicular Lymphoma August 30, 2018 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationRituximab in lymphoma: A systematic review and consensus practice guideline from Cancer Care Ontario
Cancer Treatment Reviews (2007) 33, 161 176 available at www.sciencedirect.com journal homepage: www.elsevierhealth.com/journals/ctrv ANTI-TUMOUR TREATMENT Rituximab in lymphoma: A systematic review and
More informationScottish Medicines Consortium
Scottish Medicines Consortium ibritumomab tiuxetan (Zevalin ) No. (171/05) Schering Health Care Ltd 8 April 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationevidence watch landmarks A review and assessment of recent clinical trial data Follicular non-hodgkin lymphoma Latest research profiles
Latest research profiles evidence watch A review and assessment of recent clinical trial data Oncology Exchange provides overviews of important clinical trial data presented at the 49 th Annual Meeting
More informationNon-Hodgkin lymphomas (NHLs) constitute a heterogeneous. Original Articles
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS Volume 28, Number 5, 2013 ª Mary Ann Liebert, Inc. DOI: 10.1089/cbr.2012.1387 Original Articles Phase I Study of a Modified Regimen of 90 Yttrium Ibritumomab
More informationTechnology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta243
Rituximab for the first-line treatment of stage III-IV follicular lymphoma Technology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta243 NICE 2017. All rights reserved. Subject to
More informationPhase I study of chimeric anti-cd20 monoclonal antibody in Chinese patients with CD20-positive non-hodgkin s lymphoma
Original Article Phase I study of chimeric anti-cd20 monoclonal antibody in Chinese patients with CD20-positive non-hodgkin s lymphoma Lin Gui 1*, Xiaohong Han 1*, Xiaohui He 1, Yuanyuan Song 1, Jiarui
More informationRituximab Is Potentiated by GM-CSF in Relapsed Follicular Lymphoma Patients: Results of a Phase II Study
Rituximab Is Potentiated by GM-CSF in Relapsed Follicular Lymphoma Patients: Results of a Phase II Study Guillaume Cartron MD PhD, 1-4 Zhao-Yang Lu MD PhD, 2-5 Marion Baudard MD, 1 Tarik Kanouni MD, 1
More informationRituximab, recombinant for intravenous infusion (CAS registry number: ).
MABTHERA Rituximab, recombinant for intravenous infusion (CAS registry number: 174722-31-7). WARNING Use of MABTHERA may be associated with an increased risk of progressive multifocal leukoencephalopathy
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationJOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
VOLUME 24 NUMBER 19 JULY 1 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
More informationThe Use and Effectiveness of Rituximab Maintenance in Patients with Follicular Lymphoma Diagnosed Between 2004 and 2007 in the United States
The Use and Effectiveness of Rituximab Maintenance in Patients with Follicular Lymphoma Diagnosed Between 2004 and 2007 in the United States Loretta J Nastoupil, The University of Texas MD Anderson Cancer
More informationEmerging targeted therapies for follicular lymphoma A future without chemotherapy
Emerging targeted therapies for follicular lymphoma A future without chemotherapy Pier Luigi Zinzani Institute of Hematology L. e A. Seràgnoli University of Bologna FOLLICULAR LYMPHOMA: GENERAL ASPECTS
More informationNational Horizon Scanning Centre. Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory. January 2008
Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory January 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationPalliative Low Grade Lymphoma & Hairy Cell Leukemia Regimens. Low Grade Lymphoma
Palliative Low Grade Lymphoma & Hairy Cell Leukemia Regimens The following table lists the evidence-informed regimens (both IV and non-iv) for low grade lymphoma and Hairy Cell leukemia used in the palliative
More informationDisclosures WOJCIECH JURCZAK
Disclosures WOJCIECH JURCZAK ABBVIE (RESEARCH FUNDING), CELGENE (RESEARCH FUNDING); EISAI (RESEARCH FUNDING); GILEAD (RESEARCH FUNDING); JANSEN (RESEARCH FUNDING); MORPHOSYS (RESEARCH FUNDING), MUNDIPHARMA
More informationRituximab dosing in B cell lymphoma
RESEARCH HIGHLIGHT Rituximab dosing in B cell lymphoma Yazeed Sawalha, Mitchell R. Smith Department of Medical Oncology and Hematology, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland,
More informationUpdate: New Treatment Modalities
ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe founded in 1985 Comparison of Two Consecutive Study Generations of the GLSG Overall Survival Follicular Lymphomas Questions for the Next Steps of
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 08/19/14 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
RITUXAN (rituximab) Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline
More informationSEQUENCING FOLLICULAR LYMPHOMA
SEQUENCING FOLLICULAR LYMPHOMA Thomas E. Witzig, MD October 24, 2015 Disclosures All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial
More informationIs there still a role for autotransplant with follicular lymphoma in the rituximab era. Pr. Christian Gisselbrecht Hôpital Saint Louis Paris, France
COSTEM Berlin September 8-11 211. Is there still a role for autotransplant with follicular lymphoma in the rituximab era. Pr. Christian Gisselbrecht Hôpital Saint Louis Paris, France World Health Organization
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationAdvances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma
Annals of Oncology 16 (Supplement 2): ii99 ii104, 2005 doi:10.1093/annonc/mdi724 Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma M. Dreyling, C.
More informationBiogen Idec Oncology Pipeline. Greg Reyes, MD, PhD SVP, Oncology Research & Development
Biogen Idec Oncology Pipeline Greg Reyes, MD, PhD SVP, Oncology Research & Development March 25, 2009 Biogen Idec Strategy in Lymphoma / Leukemia CLL RITUXAN NHL FC-RITUXAN GA101 RITUXAN-CVP RITUXAN-CHOP
More informationAnti-CD20 Monoclonal Antibody as a New Treatment Modality for B-Cell Lymphoma
Acta Histochem. Cytochem. 35 (4): 275 279, 2002 Review Anti-CD20 Monoclonal Antibody as a New Treatment Modality for B-Cell Lymphoma Tomomitsu Hotta 1 1 Division of Hematology and Oncology, Department
More informationNational Horizon Scanning Centre. Rituximab (MabThera) for chronic lymphocytic leukaemia. September 2007
Rituximab (MabThera) for chronic lymphocytic leukaemia This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Obinutuzumab (Gazyva) for Follicular Lymphoma November 1, 2018
pan-canadian Oncology Drug Review Final Economic Guidance Report Obinutuzumab (Gazyva) for Follicular Lymphoma November 1, 2018 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationNotification to Implement Issued by pcodr: December 14, 2012
PROVINCIAL FUNDING SUMMARY Bendamustine hydrochloride (Treanda) for indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma (first-line and relapsed/refractory) perc Recommendation: Recommends For further
More informationORIGINAL ARTICLE. Medical College Hospital, Dhaka, Bangladesh 2 Dr. Shahnaz Karim, Department Of Transfusion Medicine
ORIGINAL ARTICLE A Study on Relapsed β-cell Lymphoma in Elderly Patient of Bangladeshi Population with Rituximab, Gemcitabin and Oxaliplatin: an Effective Salvage Regimen *ME Hoque 1, S Karim 2, RS Giasuddin
More informationMANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA CLINICAL CASE PRESENTATION Martin Dreyling Medizinische Klinik III LMU München Munich, Germany esmo.org Multicenter Evaluation of MCL Annency Criteria fulfilled event free interval
More informationRiTUXimab 375 mg/m 2 Therapy-7 day
RiTUXimab 375 mg/m 2 Therapy-7 day This regimen supercedes NCCP Regimen 00208 rituximab 375mg/m2 therapy-follicular lymphoma as of February 2019 INDICATIONS FOR USE: Regimen *Reimbursement INDICATION ICD10
More informationThe role of rituximab for maintenance therapy in
COUNTERPOINTS Current Controversies in Hematology and Oncology Counterpoints Is Maintenance Therapy Necessary in Low-Grade Lymphoma? Maintenance therapy with rituximab has been shown to prolong progression-free
More informationMonoclonal Antibody Therapy in Lymphoid Malignancies. The Sarah Cannon Cancer Center, Centennial Medical Center, Nashville, Tennessee, USA
The Oncologist Promising New Drugs and Combinations Monoclonal Antibody Therapy in Lymphoid Malignancies JOHN D. HAINSWORTH The Sarah Cannon Cancer Center, Centennial Medical Center, Nashville, Tennessee,
More informationGazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
More informationPanel Discussion/References
Follicular Lymphoma (FOLL) FOLL-B category designation for first-line therapy options for FL: Bendamustine + rituximab RCHOP RCVP Submission from Genentech to review the data related to obinutuzumab for
More informationPopulation Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin s Lymphoma and Exposure Response
Citation: CPT Pharmacometrics Syst. Pharmacol. (214) 3, e144; doi:1.138/psp.214.42 214 ASCPT All rights reserved 2163-836/14 Original Article Population Pharmacokinetics of Obinutuzumab (GA11) in Chronic
More informationVariability in clinical and biological response to rituximab in autoimmune diseases: an opportunity for personalized therapy?
to International Journal of Clinical Rheumatology Variability in clinical and biological response to rituximab in autoimmune diseases: an opportunity for personalized therapy? A better understanding of
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationBC Cancer Protocol Summary for the Treatment of rituximabrefractory Follicular Lymphoma (FL) with obinutuzumab in combination with Bendamustine
BC Cancer Protocol Summary for the Treatment of rituximabrefractory Follicular Lymphoma (FL) with obinutuzumab in combination with Bendamustine Protocol Code Tumour Group Contact Physician ULYOBBEND Lymphoma
More informationPanel Discussion/References
Follicular Lymphoma (FOLL) Panel discussion to reassess the category designation for lenalidomide + rituximab as a firstline therapy for FL. Panel discussion to reassess the inclusion of radioimmunotherapy
More informationRituximab maintenance therapy of follicular lymphoma in clinical practice
Received: 20 December 2017 Revised: 10 April 2018 DOI: 10.1002/cam4.1549 Accepted: 19 April 2018 ORIGINAL RESEARCH Rituximab maintenance therapy of follicular lymphoma in clinical practice Ulrich Dührsen
More informationEconomic impact of disease progression in follicular non-hodgkin lymphoma
Leukemia & Lymphoma, November 2011; 52(11): 2117 2123 2011 Informa UK, Ltd. ISSN: 1042-8194 print / 1029-2403 online DOI: 10.3109/10428194.2011.592623 ORIGINAL ARTICLE: CLINICAL Economic impact of disease
More informationAPPROXIMATELY 50% of patients with non-
Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin s Lymphoma By J.M. Vose, B.K. Link, M.L. Grossbard, M. Czuczman, A. Grillo-Lopez,
More informationClinical Policy: Rituximab (Rituxan) Reference Number: PA.CP.PHAR.260
Clinical Policy: (Rituxan) Reference Number: PA.CP.PHAR.260 Effective Date: 01/18 Last Review Date: 04/18 Coding Implications Revision Log Description The intent of the criteria is to ensure that patients
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 5 January 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 5 January 2011 CHLORAMINOPHENE 2 mg, capsule B/30 (CIP code: 3369906) Applicant: TECHNI-PHARMA chlorambucil ATC code:
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): October 29, 2002 Most Recent Review Date (Revised): March 25, 2014 Effective Date: August 6, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationClinical Study Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan
ISRN Oncology Volume 2013, Article ID 863909, 5 pages http://dx.doi.org/10.1155/2013/863909 Clinical Study Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single
More informationTRANSPARENCY COMMITTEE OPINION. 27 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1
More informationCost-effectiveness of Obinutuzumab (Gazyvaro ) for the Treatment of Follicular Lymphoma
Cost-effectiveness of Obinutuzumab (Gazyvaro ) for the Treatment of Follicular Lymphoma The NCPE has issued a recommendation regarding the cost-effectiveness of obinutuzumab (Gazyvaro ). Following NCPE
More informationOverview. Table of Contents. A Canadian perspective provided by Isabelle Bence-Bruckler, MD, FRCPC
2 A C A N A D I A N P E R S P E C T I V E Volume 2 November 2005 Overview The International Conference on Malignant Lymphoma (ICML) is held every three years in Lugano, Switzerland. ICML started nearly
More information148 P&T March 2010 Vol. 35 No. 3
Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin s Lymphoma Efrat Dotan, MD, Charu Aggarwal, MD, MPH, and Mitchell R. Smith, MD, PhD ABSTRACT Non-Hodgkin s lymphoma (NHL) is the most
More informationGazyva (obinutuzumab)
Gazyva (obinutuzumab) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201807/01/2018 POLICY A. INDICATIONS The indications
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationMaintenance rituximab following response to first-line therapy in mantle cell lymphoma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Maintenance rituximab following response to first-line therapy in mantle cell lymphoma Maintenance rituximab following response to first-line therapy in mantle
More informationClinical and statistical considerations of bridging approaches to alternative dosing regimen or formulations
Clinical and statistical considerations of bridging approaches to alternative dosing regimen or formulations Dominik Heinzmann, PhD Global Development Team Leader Biostatistics Manager F. Hoffmann-La Roche,
More informationIl Rituximab nella ITP
Il Rituximab nella ITP Monica Carpenedo U.O.C Ematologia e TMO, Ospedale San Gerardo, Monza Burning questions about Rituximab and ITP What is the mechanism of action? What is long term effect of treatment?
More informationCLINICAL STUDY PROTOCOL PRIMA. Primary Rituximab and Maintenance
CLINICAL STUDY PROTOCOL PRIMA Primary Rituximab and Maintenance A multicentre, phase III, open-label, randomized study in patients with advanced follicular lymphoma evaluating the benefit of maintenance
More informationUnique Toxicities and Resistance Mechanisms Associated with Monoclonal Antibody Therapy
Unique Toxicities and Resistance Mechanisms Associated with Monoclonal Antibody Therapy Jonathan W. Friedberg Anti-CD20 therapy has had a truly dramatic impact on treatment and outcome of patients with
More informationFollicular Lymphoma 2016:
Follicular Lymphoma 2016: Evolving Management Strategies Randeep Sangha, MD Medical Oncology, Cross Cancer Institute Associate Professor, University of Alberta Edmonton, AB Disclosures I have no actual
More informationHow I treat High-risk follicular lymphoma
How I treat High-risk follicular lymphoma Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona 1) median OS raised from 10 to 18 y 2) advanced FL remains uncurable Stanford, n = 1334
More informationGuidelines for the diagnosis and treatment of follicular lymphoma in China
Cancer Biol Med 2013;10:36-42. doi: 10.7497/j.issn.2095-3941.2013.01.006 36 PRACTICE GUIDELINE Guidelines for the diagnosis and treatment of follicular lymphoma in China Hematology Branch of Chinese Medical
More information